BIOTRONIK Pulsar Stent Delivers Excellent Primary Patency and Freedom from TLR Rates in 12-Month 4EVER Study Results

Results show strong evidence of benefits for lower limb intervention when using Pulsar stentsBUELACH, Switzerland, November 15, 2012—BIOTRONIK  has announced the twelve-month results from the prospective, multicenter, single-arm 4EVER  study, which demonstrates the efficacy and safety of BIOTRONIK’s Pulsar self-expanding stent system in 120 superficial femoral artery (SFA) patients. Twelve-month data for the full cohort showed an impressive 81.4% primary